Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-POP: Perioperative Navlimetostat + mFOLFIRINOX in MTAP-Deleted Pancreatic Cancer
NCT07905131Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of navlimetostat in pancreatic ductal adenocarcinoma (PDAC). Planned start Jan 2027; status: not yet recruiting.
02
Drugs
navlimetostat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07905131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905131.